KALA BIO shares surge 48.12% intraday after securing $6M financing led by new CEO David Lazar and settling $7M debt with Oxford Finance.

KALA BIO surged 48.12% intraday following the announcement of a $6 million securities purchase agreement with investor David E. Lazar, who was appointed CEO and board member. The deal, disclosed in a GlobeNewswire report, included a $1.8 million initial tranche and a pending $4.2 million second tranche, alongside a $7 million debt settlement with Oxford Finance that averted asset seizure. These developments, detailed in a separate analysis, signaled financial stabilization and governance changes, sparking investor optimism. While prior clinical trial failures and significant year-to-date losses cast uncertainty, the immediate catalysts—capital infusion, leadership shift, and debt.